{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:40:47Z","timestamp":1791214847289,"version":"4.1.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s10555-009-9192-9","type":"journal-article","created":{"date-parts":[[2009,12,9]],"date-time":"2009-12-09T00:29:38Z","timestamp":1260318578000},"page":"355-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Emerging targeted therapies for bladder cancer: a disease waiting for a drug"],"prefix":"10.1007","volume":"28","author":[{"given":"Simon J.","family":"Dovedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry R.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,10]]},"reference":[{"key":"9192_CR1","first-page":"225","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225\u2013249.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"9192_CR2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrc1697","volume":"5","author":"XR Wu","year":"2005","unstructured":"Wu, X. R. (2005). Urothelial tumorigenesis: a tale of divergent pathways. Nature Reviews Cancer, 5, 713\u2013725.","journal-title":"Nature Reviews Cancer"},{"key":"9192_CR3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.onc.1204315","volume":"20","author":"ZT Zhang","year":"2001","unstructured":"Zhang, Z. T., Pak, J., Huang, H. Y., Shapiro, E., Sun, T. T., Pellicer, A., et al. (2001). Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene, 20, 1973\u20131980.","journal-title":"Oncogene"},{"key":"9192_CR4","first-page":"3512","volume":"59","author":"ZT Zhang","year":"1999","unstructured":"Zhang, Z. T., Pak, J., Shapiro, E., Sun, T. T., & Wu, X. R. (1999). Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Research, 59, 3512\u20133517.","journal-title":"Cancer Research"},{"key":"9192_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","volume":"27","author":"KD Sievert","year":"2009","unstructured":"Sievert, K. D., Amend, B., Nagele, U., et al. (2009). Economic aspects of bladder cancer: what are the benefits and costs? World Journal of Urology, 27, 295\u2013300.","journal-title":"World Journal of Urology"},{"key":"9192_CR6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","volume":"21","author":"MF Botteman","year":"2003","unstructured":"Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B., & Hauser, R. (2003). The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics, 21, 1315\u20131330.","journal-title":"Pharmacoeconomics"},{"key":"9192_CR7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"W Zou","year":"2005","unstructured":"Zou, W. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer, 5, 263\u2013274.","journal-title":"Nature Reviews Cancer"},{"key":"9192_CR8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"P Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m, P., Sylvester, R. J., Crawford, D. E., et al. (2009). An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette\u2013Gu\u00e9rin for non-muscle-invasive bladder cancer. European Urology, 56, 247\u2013256.","journal-title":"European Urology"},{"key":"9192_CR9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.rmed.2003.12.003","volume":"98","author":"A Ponticiello","year":"2004","unstructured":"Ponticiello, A., Perna, F., Maione, S., et al. (2004). Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity. Respiratory Medicine, 98, 509\u2013514.","journal-title":"Respiratory Medicine"},{"key":"9192_CR10","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1442-2042.2006.01697.x","volume":"14","author":"M Naoe","year":"2007","unstructured":"Naoe, M., Ogawa, Y., Takeshita, K., Morita, J., Iwamoto, S., Miyazaki, A., et al. (2007). Bacillus Calmette\u2013Guerin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells. International Journal of Urology, 14, 532. 8; discussion 538.","journal-title":"International Journal of Urology"},{"key":"9192_CR11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"APM van der Meijden","year":"2003","unstructured":"van der Meijden, A. P. M., Sylvester, R. J., Oosterlinck, W., Hoeltl, W., & Bono, A. V. (2003). Maintenance Bacillus Calmette\u2013Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. European Urology, 44, 429\u2013434.","journal-title":"European Urology"},{"key":"9192_CR12","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0022-5347(05)65522-X","volume":"166","author":"F Saint","year":"2001","unstructured":"Saint, F., Patard, J. J., Maille, P., et al. (2001). T Helper 1\/2 lymphocyte urinary cytokine profiles in responding and non-responding patients after 1 and 2 courses of Bacillus Calmette\u2013Guerin for superficial bladder cancer. Journal of Urology, 166, 2142\u20132147.","journal-title":"Journal of Urology"},{"key":"9192_CR13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","volume":"131","author":"R Nadler","year":"2003","unstructured":"Nadler, R., Luo, Y., Zhao, W., et al. (2003). Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis Bacillus Calmette\u2013Guerin (BCG) mediated antitumour activity. Clinical and Experimental Immunology, 131, 206\u2013216.","journal-title":"Clinical and Experimental Immunology"},{"key":"9192_CR14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","volume":"167","author":"F Saint","year":"2002","unstructured":"Saint, F., Patard, J. J., Maille, P., et al. (2002). Prognostic value of a T helper 1 urinary cytokine response after intravesical Bacillus Calmette\u2013Guerin treatment for superficial bladder cancer. Journal of Urology, 167, 364\u2013367.","journal-title":"Journal of Urology"},{"key":"9192_CR15","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","volume":"162","author":"Y Luo","year":"1999","unstructured":"Luo, Y., Chen, X., Downs, T. M., DeWolf, W. C., & O'Donnell, M. A. (1999). IFN-{alpha} 2B enhances Th1 cytokine responses in bladder cancer patients receiving mycobacterium bovis Bacillus Calmette\u2013Guerin immunotherapy. Journal of Immunology, 162, 2399\u20132405.","journal-title":"Journal of Immunology"},{"key":"9192_CR16","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1158\/0008-5472.CAN-04-1909","volume":"64","author":"A Papageorgiou","year":"2004","unstructured":"Papageorgiou, A., Lashinger, L., Millikan, R., Grossman, H. B., Benedict, W., Dinney, C. P., et al. (2004). Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Research, 64, 8973\u20138979.","journal-title":"Cancer Research"},{"key":"9192_CR17","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/1535-7163.MCT-05-0474","volume":"5","author":"A Papageorgiou","year":"2006","unstructured":"Papageorgiou, A., Kamat, A., Benedict, W. F., Dinney, C., & McConkey, D. J. (2006). Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Molecular Cancer Therapeutics, 5, 3032\u20133041.","journal-title":"Molecular Cancer Therapeutics"},{"key":"9192_CR18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","volume":"71","author":"BL Gallagher","year":"2008","unstructured":"Gallagher, B. L., Joudi, F. N., Maym\u00ed, J. L., & O\u2019Donnell, M. A. (2008). Impact of previous Bacille Calmette\u2013Gu\u00e9rin failure pattern on subsequent response to Bacille Calmette\u2013Gu\u00e9rin plus interferon intravesical therapy. Urology, 71, 297\u2013301.","journal-title":"Urology"},{"key":"9192_CR19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00345-009-0429-6","volume":"27","author":"KG Nepple","year":"2009","unstructured":"Nepple, K. G., Aubert, H. A., Braasch, M. R., & O'Donnell, M. A. (2009). Combination of BCG and interferon intravesical immunotherapy: an update. World Journal of Urology, 27, 343\u2013346.","journal-title":"World Journal of Urology"},{"key":"9192_CR20","first-page":"5647","volume":"59","author":"SI Mohammed","year":"1999","unstructured":"Mohammed, S. I., Knapp, D. W., Bostwick, D. G., et al. (1999). Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Research, 59, 5647\u20135650.","journal-title":"Cancer Research"},{"key":"9192_CR21","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0022-5347(05)64522-3","volume":"168","author":"MA Wheeler","year":"2002","unstructured":"Wheeler, M. A., Hausladen, D. A., Yoon, J. H., & Weiss, R. M. (2002). Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. Journal of Urology, 168, 1568\u20131573.","journal-title":"Journal of Urology"},{"key":"9192_CR22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0090-4295(02)01909-X","volume":"60","author":"SIl Kim","year":"2002","unstructured":"Kim, S Il, Kwon, S. M., Kim, Y. S., & Hong, S. J. (2002). Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology, 60, 816\u2013821.","journal-title":"Urology"},{"key":"9192_CR23","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1158\/0008-5472.CAN-05-0216","volume":"65","author":"K Krysan","year":"2005","unstructured":"Krysan, K., Reckamp, K. L., Dalwadi, H., Sharma, S., Rozengurt, E., Dohadwala, M., et al. (2005). Prostaglandin E2 activates mitogen-activated protein kinase\/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Research, 65, 6275\u20136281.","journal-title":"Cancer Research"},{"key":"9192_CR24","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1158\/0008-5472.CAN-04-3671","volume":"65","author":"D Wang","year":"2005","unstructured":"Wang, D., Buchanan, F. G., Wang, H., Dey, S. K., & DuBois, R. N. (2005). Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Research, 65, 1822\u20131829.","journal-title":"Cancer Research"},{"key":"9192_CR25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nm0302-289","volume":"8","author":"R Pai","year":"2002","unstructured":"Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., & Tarnawski, A. S. (2002). Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Medicine, 8, 289\u2013293.","journal-title":"Nature Medicine"},{"key":"9192_CR26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00262-008-0584-4","volume":"58","author":"M Herfs","year":"2009","unstructured":"Herfs, M., Herman, L., Hubert, P., et al. (2009). High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunology, Immunotherapy, 58, 603\u2013614.","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"9192_CR27","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/0008-5472.CAN-05-0141","volume":"65","author":"S Sharma","year":"2005","unstructured":"Sharma, S., Yang, S., Zhu, L., et al. (2005). Tumor cyclooxygenase-2\/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Research, 65, 5211\u20135220.","journal-title":"Cancer Research"},{"key":"9192_CR28","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.4049\/jimmunol.168.5.2255","volume":"168","author":"H Harizi","year":"2002","unstructured":"Harizi, H., Juzan, M., Pitard, V., Moreau, J. F., & Gualde, N. (2002). Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. Journal of Immunology, 168, 2255\u20132263.","journal-title":"Journal of Immunology"},{"key":"9192_CR29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.ju.0000161589.85869.ae","volume":"174","author":"SJ Dovedi","year":"2005","unstructured":"Dovedi, S. J., Kirby, J. A., Atkins, H., Davies, B. R., & Kelly, J. D. (2005). Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of Bacillus Calmette\u2013Guerin immunotherapy for bladder cancer. Journal of Urology, 174, 332. 7; discussion 337.","journal-title":"Journal of Urology"},{"key":"9192_CR30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2008.01.013","volume":"54","author":"SJ Dovedi","year":"2008","unstructured":"Dovedi, S. J., Kirby, J. A., Davies, B. R., Leung, H., & Kelly, J. D. (2008). Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. European Urology, 54, 621\u2013630.","journal-title":"European Urology"},{"key":"9192_CR31","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.4049\/jimmunol.158.4.1742","volume":"158","author":"M Chambers","year":"1997","unstructured":"Chambers, M., Marshall, B., Wangoo, A., Bune, A., Cook, H., Shaw, R., et al. (1997). Differential responses to challenge with live and dead Mycobacterium bovis Bacillus Calmette\u2013Guerin. Journal of Immunology, 158, 1742\u20131748.","journal-title":"Journal of Immunology"},{"key":"9192_CR32","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/41131","volume":"388","author":"R Medzhitov","year":"1997","unstructured":"Medzhitov, R., Preston-Hurlburt, P., & Janeway, C. A., Jr. (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 388, 394\u2013397.","journal-title":"Nature"},{"key":"9192_CR33","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/sj.bjc.6601474","volume":"89","author":"H Atkins","year":"2003","unstructured":"Atkins, H., Davies, B. R., Kirby, J. A., & Kelly, J. D. (2003). Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. British Journal of Cancer, 89, 2312\u20132319.","journal-title":"British Journal of Cancer"},{"key":"9192_CR34","first-page":"2067","volume":"29","author":"PJ Olbert","year":"2009","unstructured":"Olbert, P. J., Schrader, A. J., Simon, C., Dalpke, A., Barth, P., Hofmann, R., et al. (2009). In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall. Anticancer Research, 29, 2067\u20132076.","journal-title":"Anticancer Research"},{"key":"9192_CR35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/CJI.0b013e3181587d29","volume":"31","author":"SM Mangsbo","year":"2008","unstructured":"Mangsbo, S. M., Ninalga, C., Essand, M., Loskog, A., & Totterman, T. H. (2008). CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. Journal of Immunotherapy, 31, 34\u201342.","journal-title":"Journal of Immunotherapy"},{"key":"9192_CR36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bjc.6690038","volume":"79","author":"MC Filion","year":"1999","unstructured":"Filion, M. C., Lepicier, P., Morales, A., & Phillips, N. C. (1999). Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. British Journal of Cancer, 79, 229\u2013235.","journal-title":"British Journal of Cancer"},{"key":"9192_CR37","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1038\/sj.onc.1210466","volume":"26","author":"M Kanehira","year":"2007","unstructured":"Kanehira, M., Harada, Y., Takata, R., et al. (2007). Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene, 26, 6448\u20136455.","journal-title":"Oncogene"},{"key":"9192_CR38","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1158\/0008-5472.CAN-06-3748","volume":"67","author":"M Kanehira","year":"2007","unstructured":"Kanehira, M., Katagiri, T., Shimo, A., et al. (2007). Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Research, 67, 3276\u20133285.","journal-title":"Cancer Research"},{"key":"9192_CR39","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/ijc.24503","volume":"125","author":"A Bergeron","year":"2009","unstructured":"Bergeron, A., Picard, V., LaRue, H., Harel, F., Hovington, H., Lacombe, L., et al. (2009). High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. International Journal of Cancer, 125, 1365\u20131371.","journal-title":"International Journal of Cancer"},{"key":"9192_CR40","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/CJI.0b013e3181891574","volume":"31","author":"P Sharma","year":"2008","unstructured":"Sharma, P., Bajorin, D. F., Jungbluth, A. A., Herr, H., Old, L. J., & Gnjatic, S. (2008). Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. Journal of Immunotherapy, 31, 849\u2013857.","journal-title":"Journal of Immunotherapy"},{"key":"9192_CR41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/12615","volume":"23","author":"D Cappellen","year":"1999","unstructured":"Cappellen, D., De Oliveira, C., Ricol, D., et al. (1999). Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genetics, 23, 18\u201320.","journal-title":"Nature Genetics"},{"key":"9192_CR42","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","volume":"158","author":"C Billerey","year":"2001","unstructured":"Billerey, C., Chopin, D., Aubriot-Lorton, M. H., et al. (2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. American Journal of Pathology, 158, 1955\u20131959.","journal-title":"American Journal of Pathology"},{"key":"9192_CR43","first-page":"1265","volume":"61","author":"BW van Rhijn","year":"2001","unstructured":"van Rhijn, B. W., Lurkin, I., Radvanyi, F., Kirkels, W. J., van der Kwast, T. H., & Zwarthoff, E. C. (2001). The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Research, 61, 1265\u20131268.","journal-title":"Cancer Research"},{"key":"9192_CR44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","volume":"213","author":"DC Tomlinson","year":"2007","unstructured":"Tomlinson, D. C., Baldo, O., Harnden, P., & Knowles, M. A. (2007). FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. Journal of Pathology, 213, 91\u201398.","journal-title":"Journal of Pathology"},{"key":"9192_CR45","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/carcin\/bgi290","volume":"27","author":"I Bernard-Pierrot","year":"2006","unstructured":"Bernard-Pierrot, I., Brams, A., Dunois-Larde, C., et al. (2006). Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis, 27, 740\u2013747.","journal-title":"Carcinogenesis"},{"key":"9192_CR46","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1038\/sj.onc.1210399","volume":"26","author":"DC Tomlinson","year":"2007","unstructured":"Tomlinson, D. C., Hurst, C. D., & Knowles, M. A. (2007). Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene, 26, 5889\u20135899.","journal-title":"Oncogene"},{"key":"9192_CR47","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.1158\/0008-5472.CAN-06-2044","volume":"66","author":"CL Chaffer","year":"2006","unstructured":"Chaffer, C. L., Brennan, J. P., Slavin, J. L., Blick, T., Thompson, E. W., & Williams, E. D. (2006). Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Research, 66, 11271\u201311278.","journal-title":"Cancer Research"},{"key":"9192_CR48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.onc.1200830","volume":"14","author":"SG Diez de Medina","year":"1997","unstructured":"Diez de Medina SG, Chopin, D., El Marjou, A., et al. (1997). Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene, 14, 323\u2013330.","journal-title":"Oncogene"},{"key":"9192_CR49","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1158\/0008-5472.CAN-08-2816","volume":"69","author":"DC Tomlinson","year":"2009","unstructured":"Tomlinson, D. C., Lamont, F. R., Shnyder, S. D., & Knowles, M. A. (2009). Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Research, 69, 4613\u20134620.","journal-title":"Cancer Research"},{"key":"9192_CR50","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI38017","volume":"119","author":"J Qing","year":"2009","unstructured":"Qing, J., Du, X., Chen, Y., et al. (2009). Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. Journal of Clinical Investigation, 119, 1216\u20131229.","journal-title":"Journal of Clinical Investigation"},{"key":"9192_CR51","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","volume":"24","author":"AH Jebar","year":"2005","unstructured":"Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F., & Knowles, M. A. (2005). FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene, 24, 5218\u20135225.","journal-title":"Oncogene"},{"key":"9192_CR52","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","volume":"15","author":"FM Platt","year":"2009","unstructured":"Platt, F. M., Hurst, C. D., Taylor, C. F., Gregory, W. M., Harnden, P., & Knowles, M. A. (2009). Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clinical Cancer Research, 15, 6008\u20136017.","journal-title":"Clinical Cancer Research"},{"key":"9192_CR53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urolonc.2004.12.012","volume":"23","author":"E Winquist","year":"2005","unstructured":"Winquist, E., Moore, M. J., Chi, K. N., et al. (2005). A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol, 23, 143\u2013149.","journal-title":"Urol Oncol"},{"key":"9192_CR54","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.21023","volume":"103","author":"JE Rosenberg","year":"2005","unstructured":"Rosenberg, J. E., von der Maase, H., Seigne, J. D., et al. (2005). A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer, 103, 2035\u20132041.","journal-title":"Cancer"},{"key":"9192_CR55","first-page":"5656","volume":"63","author":"TB Brunner","year":"2003","unstructured":"Brunner, T. B., Hahn, S. M., Gupta, A. K., Muschel, R. J., McKenna, W. G., & Bernhard, E. J. (2003). Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Research, 63, 5656\u20135668.","journal-title":"Cancer Research"},{"key":"9192_CR56","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/1535-7163.MCT-07-0231","volume":"6","author":"BR Davies","year":"2007","unstructured":"Davies, B. R., Logie, A., McKay, J. S., et al. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase 1\/2 kinases: mechanism of action in vivo, pharmacokinetic\/pharmacodynamic relationship, and potential for combination in preclinical models. Molecular Cancer Therapeutics, 6, 2209\u20132219.","journal-title":"Molecular Cancer Therapeutics"},{"key":"9192_CR57","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.juro.2007.08.087","volume":"179","author":"W Kassouf","year":"2008","unstructured":"Kassouf, W., Black, P. C., Tuziak, T., et al. (2008). Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. Journal of Urology, 179, 353\u2013358.","journal-title":"Journal of Urology"},{"key":"9192_CR58","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/annonc\/mdn749","volume":"20","author":"GK Philips","year":"2009","unstructured":"Philips, G. K., Halabi, S., Sanford, B. L., Bajorin, D., Small, E. J., & for the Cancer and Leukemia Group B. (2009). A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Annals of Oncology, 20, 1074\u20131079.","journal-title":"Annals of Oncology"},{"key":"9192_CR59","first-page":"4874","volume":"6","author":"K Inoue","year":"2000","unstructured":"Inoue, K., Slaton, J. W., Perrotte, P., et al. (2000). Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clinical Cancer Research, 6, 4874\u20134884.","journal-title":"Clinical Cancer Research"},{"key":"9192_CR60","first-page":"257","volume":"5","author":"P Perrotte","year":"1999","unstructured":"Perrotte, P., Matsumoto, T., Inoue, K., et al. (1999). Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clinical Cancer Research, 5, 257\u2013265.","journal-title":"Clinical Cancer Research"},{"key":"9192_CR61","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J., Bell, D. W., Sordella, R., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350, 2129\u20132139.","journal-title":"New England Journal of Medicine"},{"key":"9192_CR62","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00345-007-0202-7","volume":"25","author":"GJ Villares","year":"2007","unstructured":"Villares, G. J., Zigler, M., Blehm, K., Bogdan, C., McConkey, D., Colin, D., et al. (2007). Targeting EGFR in bladder cancer. World Journal of Urology, 25, 573\u2013579.","journal-title":"World Journal of Urology"},{"key":"9192_CR63","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.juro.2007.05.113","volume":"178","author":"MA Jacobs","year":"2007","unstructured":"Jacobs, M. A., Wotkowicz, C., Baumgart, E. D., et al. (2007). Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib. Journal of Urology, 178, 1510\u20131514.","journal-title":"Journal of Urology"},{"key":"9192_CR64","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-06-0407","volume":"12","author":"KN Blehm","year":"2006","unstructured":"Blehm, K. N., Spiess, P. E., Bondaruk, J. E., et al. (2006). Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clinical Cancer Research, 12, 4671\u20134677.","journal-title":"Clinical Cancer Research"},{"key":"9192_CR65","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1158\/1078-0432.CCR-07-1593","volume":"14","author":"PC Black","year":"2008","unstructured":"Black, P. C., Brown, G. A., Inamoto, T., et al. (2008). Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clinical Cancer Research, 14, 1478\u20131486.","journal-title":"Clinical Cancer Research"},{"key":"9192_CR66","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.24337","volume":"115","author":"C Wulfing","year":"2009","unstructured":"Wulfing, C., Machiels, J. P., Richel, D. J., et al. (2009). A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer, 115, 2881\u20132890.","journal-title":"Cancer"},{"key":"9192_CR67","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","volume":"25","author":"MH Hussain","year":"2007","unstructured":"Hussain, M. H., MacVicar, G. R., Petrylak, D. P., et al. (2007). Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. Journal of Clinical Oncology, 25, 2218\u20132224.","journal-title":"Journal of Clinical Oncology"},{"key":"9192_CR68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","volume":"6","author":"LC Kim","year":"2009","unstructured":"Kim, L. C., Song, L., & Haura, E. B. (2009). Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol, 6, 587\u2013595.","journal-title":"Nat Rev Clin Oncol"},{"key":"9192_CR69","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman, J. A. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature Reviews Cancer, 9, 550\u2013562.","journal-title":"Nature Reviews Cancer"},{"key":"9192_CR70","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/sj.onc.1201154","volume":"14","author":"D Cappellen","year":"1997","unstructured":"Cappellen, D., Gil Diez de Medina, S., Chopin, D., Thiery, J. P., & Radvanyi, F. (1997). Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene, 14, 3059\u20133066.","journal-title":"Oncogene"},{"key":"9192_CR71","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/sj.onc.1201855","volume":"16","author":"P Cairns","year":"1998","unstructured":"Cairns, P., Evron, E., Okami, K., et al. (1998). Point mutation and homozygous deletion of PTEN\/MMAC1 in primary bladder cancers. Oncogene, 16, 3215\u20133218.","journal-title":"Oncogene"},{"key":"9192_CR72","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.bjc.6690439","volume":"80","author":"JS Aveyard","year":"1999","unstructured":"Aveyard, J. S., Skilleter, A., Habuchi, T., & Knowles, M. A. (1999). Somatic mutation of PTEN in bladder carcinoma. British Journal of Cancer, 80, 904\u2013908.","journal-title":"British Journal of Cancer"},{"key":"9192_CR73","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s002400000131","volume":"28","author":"Z Wang","year":"2000","unstructured":"Wang, Z., Zhang, Z., Liu, Y., et al. (2000). Effect of retinoic acid and its complexes with transition metals on human bladder cancer cell line EJ in vitro. Urological Research, 28, 191\u2013195.","journal-title":"Urological Research"},{"key":"9192_CR74","doi-asserted-by":"crossref","first-page":"8389","DOI":"10.1158\/0008-5472.CAN-05-4627","volume":"66","author":"H Tsuruta","year":"2006","unstructured":"Tsuruta, H., Kishimoto, H., Sasaki, T., et al. (2006). Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Research, 66, 8389\u20138396.","journal-title":"Cancer Research"},{"key":"9192_CR75","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","volume":"66","author":"E Lopez-Knowles","year":"2006","unstructured":"Lopez-Knowles, E., Hernandez, S., Malats, N., et al. (2006). PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Research, 66, 7401\u20137404.","journal-title":"Cancer Research"},{"key":"9192_CR76","first-page":"7652","volume":"63","author":"MA Knowles","year":"2003","unstructured":"Knowles, M. A., Habuchi, T., Kennedy, W., & Cuthbert-Heavens, D. (2003). Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Research, 63, 7652\u20137656.","journal-title":"Cancer Research"},{"key":"9192_CR77","first-page":"1671","volume":"11","author":"T Habuchi","year":"1995","unstructured":"Habuchi, T., Devlin, J., Elder, P. A., & Knowles, M. A. (1995). Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene, 11, 1671\u20131674.","journal-title":"Oncogene"},{"key":"9192_CR78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.urolonc.2008.03.017","volume":"27","author":"G Sonpavde","year":"2009","unstructured":"Sonpavde, G., Jian, W., Liu, H., Wu, M. F., Shen, S. S., & Lerner, S. P. (2009). Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol, 27, 391\u2013399.","journal-title":"Urol Oncol"},{"key":"9192_CR79","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1158\/0008-5472.CAN-2879-2","volume":"64","author":"DW Davis","year":"2004","unstructured":"Davis, D. W., Inoue, K., Dinney, C. P., Hicklin, D. J., Abbruzzese, J. L., & McConkey, D. J. (2004). Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253\u00a0J B-V bladder cancer xenografts. Cancer Research, 64, 4601\u20134610.","journal-title":"Cancer Research"},{"key":"9192_CR80","first-page":"2635","volume":"6","author":"K Inoue","year":"2000","unstructured":"Inoue, K., Slaton, J. W., Davis, D. W., et al. (2000). Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clinical Cancer Research, 6, 2635\u20132643.","journal-title":"Clinical Cancer Research"},{"key":"9192_CR81","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nrd2656","volume":"7","author":"A Vazquez","year":"2008","unstructured":"Vazquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008). The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov, 7, 979\u2013987.","journal-title":"Nat Rev Drug Discov"},{"key":"9192_CR82","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1158\/1078-0432.CCR-09-0096","volume":"15","author":"E Bolderson","year":"2009","unstructured":"Bolderson, E., Richard, D. J., Zhou, B. B., & Khanna, K. K. (2009). Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clinical Cancer Research, 15, 6314\u20136320.","journal-title":"Clinical Cancer Research"},{"key":"9192_CR83","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1200\/JCO.2002.20.4.957","volume":"20","author":"J Kuball","year":"2002","unstructured":"Kuball, J., Wen, S. F., Leissner, J., et al. (2002). Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. Journal of Clinical Oncology, 20, 957\u2013965.","journal-title":"Journal of Clinical Oncology"},{"key":"9192_CR84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0094-0143(05)70238-X","volume":"27","author":"JT Hsieh","year":"2000","unstructured":"Hsieh, J. T., Dinney, C. P., & Chung, L. W. (2000). The potential role of gene therapy in the treatment of bladder cancer. Urologic Clinics of North America, 27, 103. 13, ix.","journal-title":"Urologic Clinics of North America"},{"key":"9192_CR85","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s003450050188","volume":"18","author":"LC Pagliaro","year":"2000","unstructured":"Pagliaro, L. C. (2000). Gene therapy for bladder cancer. World Journal of Urology, 18, 148\u2013151.","journal-title":"World Journal of Urology"},{"key":"9192_CR86","first-page":"325","volume":"59","author":"Y Li","year":"1999","unstructured":"Li, Y., Pong, R. C., Bergelson, J. M., et al. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Research, 59, 325\u2013330.","journal-title":"Cancer Research"},{"key":"9192_CR87","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.ju.0000070925.10039.23","volume":"170","author":"DR Siemens","year":"2003","unstructured":"Siemens, D. R., Crist, S., Austin, J. C., Tartaglia, J., & Ratliff, T. L. (2003). Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model. Journal of Urology, 170, 979\u2013984.","journal-title":"Journal of Urology"},{"key":"9192_CR88","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/01.ju.0000143196.37008.2c","volume":"173","author":"I Fodor","year":"2005","unstructured":"Fodor, I., Timiryasova, T., Denes, B., Yoshida, J., Ruckle, H., & Lilly, M. (2005). Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. Journal of Urology, 173, 604\u2013609.","journal-title":"Journal of Urology"},{"key":"9192_CR89","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-03-0099","volume":"10","author":"E Kikuchi","year":"2004","unstructured":"Kikuchi, E., Menendez, S., Ohori, M., Cordon-Cardo, C., Kasahara, N., & Bochner, B. H. (2004). Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clinical Cancer Research, 10, 1835\u20131842.","journal-title":"Clinical Cancer Research"},{"key":"9192_CR90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.cgt.7700865","volume":"13","author":"Z Tao","year":"2006","unstructured":"Tao, Z., Connor, R. J., Ashoori, F., Dinney, C. P., Munsell, M., Philopena, J. A., et al. (2006). Efficacy of a single intravesical treatment with Ad-IFN\/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Therapy, 13, 125\u2013130.","journal-title":"Cancer Gene Therapy"},{"key":"9192_CR91","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1586\/14737140.1.4.531","volume":"1","author":"CJ Rosser","year":"2001","unstructured":"Rosser, C. J., Benedict, W. F., & Dinney, C. P. (2001). Gene therapy for superficial bladder cancer. Expert Rev Anticancer Ther, 1, 531\u2013539.","journal-title":"Expert Rev Anticancer Ther"},{"key":"9192_CR92","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.cgt.7700488","volume":"9","author":"M Yamashita","year":"2002","unstructured":"Yamashita, M., Rosser, C. J., Zhou, J. H., et al. (2002). Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Therapy, 9, 687\u2013691.","journal-title":"Cancer Gene Therapy"},{"key":"9192_CR93","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1074\/jbc.275.8.5600","volume":"275","author":"PR Graves","year":"2000","unstructured":"Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., et al. (2000). The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. Journal of Biological Chemistry, 275, 5600\u20135605.","journal-title":"Journal of Biological Chemistry"},{"key":"9192_CR94","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1517\/13543784.17.9.1331","volume":"17","author":"S Ashwell","year":"2008","unstructured":"Ashwell, S., Janetka, J. W., & Zabludoff, S. (2008). Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opinion on Investigational Drugs, 17, 1331\u20131340.","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"9192_CR95","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1535-7163.MCT-08-0492","volume":"7","author":"SD Zabludoff","year":"2008","unstructured":"Zabludoff, S. D., Deng, C., Grondine, M. R., et al. (2008). AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Molecular Cancer Therapeutics, 7, 2955\u20132966.","journal-title":"Molecular Cancer Therapeutics"},{"key":"9192_CR96","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1535-7163.MCT-07-2391","volume":"7","author":"A Blasina","year":"2008","unstructured":"Blasina, A., Hallin, J., Chen, E., et al. (2008). Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Molecular Cancer Therapeutics, 7, 2394\u20132404.","journal-title":"Molecular Cancer Therapeutics"},{"key":"9192_CR97","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.coph.2008.06.011","volume":"8","author":"CN Oldenhuis","year":"2008","unstructured":"Oldenhuis, C. N., Stegehuis, J. H., Walenkamp, A. M., de Jong, S., & de Vries, E. G. (2008). Targeting TRAIL death receptors. Current Opinion in Pharmacology, 8, 433\u2013439.","journal-title":"Current Opinion in Pharmacology"},{"key":"9192_CR98","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1158\/1078-0432.CCR-07-0251","volume":"13","author":"R Koschny","year":"2007","unstructured":"Koschny, R., Holland, H., Sykora, J., et al. (2007). Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clinical Cancer Research, 13, 3403\u20133412.","journal-title":"Clinical Cancer Research"},{"key":"9192_CR99","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-06-4274","volume":"67","author":"X Liu","year":"2007","unstructured":"Liu, X., Yue, P., Chen, S., Hu, L., Lonial, S., Khuri, F. R., et al. (2007). The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Research, 67, 4981\u20134988.","journal-title":"Cancer Research"},{"key":"9192_CR100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1476-4598-6-73","volume":"6","author":"J Voortman","year":"2007","unstructured":"Voortman, J., Checinska, A., & Giaccone, G. (2007). The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer, 6, 73.","journal-title":"Mol Cancer"},{"key":"9192_CR101","doi-asserted-by":"crossref","first-page":"5528s","DOI":"10.1158\/1078-0432.CCR-07-0982","volume":"13","author":"MR Smith","year":"2007","unstructured":"Smith, M. R., Jin, F., & Joshi, I. (2007). Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clinical Cancer Research, 13, 5528s\u20135534s.","journal-title":"Clinical Cancer Research"},{"key":"9192_CR102","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10637-006-9009-4","volume":"25","author":"G Gomez-Abuin","year":"2007","unstructured":"Gomez-Abuin, G., Winquist, E., Stadler, W. M., Pond, G., Degendorfer, P., Wright, J., et al. (2007). A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Investigational New Drugs, 25, 181\u2013185.","journal-title":"Investigational New Drugs"},{"key":"9192_CR103","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/annonc\/mdm600","volume":"19","author":"JE Rosenberg","year":"2008","unstructured":"Rosenberg, J. E., Halabi, S., Sanford, B. L., et al. (2008). Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Annals of Oncology, 19, 946\u2013950.","journal-title":"Annals of Oncology"},{"key":"9192_CR104","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1535-7163.279.3.3","volume":"3","author":"AM Kamat","year":"2004","unstructured":"Kamat, A. M., Karashima, T., Davis, D. W., et al. (2004). The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Molecular Cancer Therapeutics, 3, 279\u2013290.","journal-title":"Molecular Cancer Therapeutics"},{"key":"9192_CR105","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1172\/JCI23043","volume":"115","author":"M Nogawa","year":"2005","unstructured":"Nogawa, M., Yuasa, T., Kimura, S., et al. (2005). Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. Journal of Clinical Investigation, 115, 978\u2013985.","journal-title":"Journal of Clinical Investigation"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-009-9192-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-009-9192-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-009-9192-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-009-9192-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T17:48:55Z","timestamp":1684864135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-009-9192-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":105,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["9192"],"URL":"https:\/\/doi.org\/10.1007\/s10555-009-9192-9","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"10 December 2009","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}